Black Rock Inc. Humanigen, Inc Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.13 - $0.2 $27,679 - $42,584	-212,922 Reduced 20.77%	812,398 $121,000
Q1 2023 May 12, 2023	BUY	$0.12 - $0.23 $9,497 - $18,202	79,142 Added 8.36%	1,025,320 $143,000
Q4 2022 Feb 13, 2023	BUY	$0.09 - $0.2 $66 - $148	740 Added 0.08%	946,178 $113,000
Q3 2022 Nov 14, 2022	SELL	$0.15 - $3.02 $623 - $12,551	-4,156 Reduced 0.44%	945,438 $170,000
Q2 2022 Aug 12, 2022	SELL	$1.76 - $3.33 $4.25 Million - $8.05 Million	-2,417,421 Reduced 71.8%	949,594 $1.68 Million
Q1 2022 May 12, 2022	BUY	$1.81 - $3.97 $42,019 - $92,163	23,215 Added 0.69%	3,367,015 $10.1 Million
Q4 2021 Feb 10, 2022	BUY	$3.66 - $8.22 $912,489 - $2.05 Million	249,314 Added 8.06%	3,343,800 $12.4 Million
Q3 2021 Nov 09, 2021	BUY	$5.93 - $17.83 $336,782 - $1.01 Million	56,793 Added 1.87%	3,094,486 $18.3 Million
Q2 2021 Aug 11, 2021	BUY	$13.54 - $22.74 $41.1 Million - $69.1 Million	3,037,693 New	3,037,693 $52.8 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.